Evidence map›Paper›PMID 26852130›Full record

ArticleBMC medical genetics2016

Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.

Giulia Cini, Massimo Mezzavilla, Lara Della Puppa, Elisa Cupelli, Alessio Fornasin, Angela Valentina D'Elia, Riccardo Dolcetti, Giuseppe Damante, Sara Bertok, Gianmaria Miolo and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC medical genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Analysis of ItalianCancers · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Giulia CiniExperimental Oncology 1, CRO Aviano National Cancer Institute, Aviano, PN, Italy.
Massimo MezzavillaInstitute for Maternal and Child Health, IRCCS "Burlo Garofalo", Trieste, Italy.
Lara Della PuppaExperimental Oncology 1, CRO Aviano National Cancer Institute, Aviano, PN, Italy.
Elisa CupelliInstitute of Hematology, Catholic University S. Cuore, Rome, Italy.
Alessio FornasinDepartment of Economics and Statistics, University of Udine, Udine, Italy.
Angela Valentina D'EliaDepartment of Medical and Biological Sciences, University of Udine, Udine, Italy.
Riccardo DolcettiCancer Bioimmunotherapy Unit, CRO Aviano National Cancer Institute, Aviano, PN, Italy.
Giuseppe DamanteDepartment of Medical and Biological Sciences, University of Udine, Udine, Italy.
Sara BertokDepartment of Endocrinology; Diabetes and Metabolic Disease, Division of Pediatrics, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Gianmaria MioloMedical Oncology B, CRO Aviano National Cancer Institute, Aviano, PN, Italy.
Roberta MaestroExperimental Oncology 1, CRO Aviano National Cancer Institute, Aviano, PN, Italy.
Paolo de PaoliScientific Directorate; CRO National Cancer Institute, Aviano, PN, Italy.
Antonio AmorosoDepartment of Medical Sciences, University of Torino, Torino, Italy.
Alessandra VielExperimental Oncology 1, CRO Aviano National Cancer Institute, Aviano, PN, Italy. aviel@cro.it.
Centro di Riferimento Oncologico · ITUniversity of Udine · ITIRCCS Materno Infantile Burlo Garofolo · ITLjubljana University Medical Centre · SIUniversità Cattolica del Sacro Cuore · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAbout 20 % of hereditary breast cancers are caused by mutations in BRCA1 and BRCA2 genes. Since BRCA1 and BRCA2 mutations may be spread throughout the gene, genetic testing is usually performed by direct sequencing of entire coding regions. In some populations, especially if relatively isolated, a few number of recurrent mutations is reported, sometimes caused by founder effect.

methodsBRCA1 and BRCA2 screening for mutations was carried out on 1114 breast and/or ovarian cancer patients complying with the eligibility criteria for BRCA testing. Haplotype analysis was performed on the probands carrying recurrent mutations and their relatives, using two sets of microsatellite markers covering the BRCA1 (D17S588, D17S806, D17S902, D17S1325, D17S855, D17S1328, D17S800, and D17S250) and BRCA2 (D13S220, D13S267, D13S171, D13S1701, D13S1698, D13S260, D13S290, D13S1246) loci. The DMLE + 2.2 software was used to estimate the age of BRCA1 c.676delT and BRCA2 c.7806-2A > G. A multiplex PCR and two different primer extension assays were optimized and used for genotyping the recurrent mutations of the two genes.

resultsIn the time frame of almost 20 years of genetic testing, we have found that five BRCA1 and three BRCA2 mutations are recurrent in a substantial subset of carriers from North-East Italy and neighboring Istria, where they represent more than 50 % of all mutations. Microsatellite analyses identified a common haplotype of different length for each mutation. Age estimation of BRCA1 c.676delT and BRCA2 c.7806-2A > G mutations revealed that they arose in the Friuli Venezia Giulia area about 86 and 94 generations ago, respectively. Suggestion of an association between BRCA2 c.7806-2A > G and risk of breast cancer in males has emerged. Finally, we developed a simple and efficient pre-screening test, performing an in-house primer extension SNaPshot® assay for the rapid identification of the eight recurrent mutations.

conclusionsProofs of common ancestry has been obtained for the eight recurrent mutations. The observed genotype-phenotype correlation and the proposed rapid mutation detection strategy could improve the clinical management of breast and ovarian patients in North-East of Italy and neighboring geographic areas.

Indexed as

DNA Mutational AnalysisAdultAgedAllelesBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsCase-Control StudiesFemaleFounder EffectGenetic TestingGenome-Wide Association StudyGenotyping TechniquesHaplotypesHumansItalyBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, human

Identifiers

PMID26852130
PMCPMC4744627
OpenAlexW2258689756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.